Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImmunoADAPT
NCT03573648Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2018
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab, palbociclib in breast cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Nov 2018; status: active, not recruiting.
02
Drugs
avelumabpalbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03573648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03573648.